S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:PRAX

Praxis Precision Medicines (PRAX) Stock Price, News & Analysis

$46.89
+0.30 (+0.64%)
(As of 04/19/2024 ET)
Today's Range
$45.60
$48.19
50-Day Range
$40.20
$62.18
52-Week Range
$12.45
$67.21
Volume
350,086 shs
Average Volume
318,454 shs
Market Capitalization
$620.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$103.00

Praxis Precision Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
119.7% Upside
$103.00 Price Target
Short Interest
Healthy
2.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Praxis Precision Medicines in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($8.64) to ($9.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

677th out of 907 stocks

Pharmaceutical Preparations Industry

310th out of 424 stocks

PRAX stock logo

About Praxis Precision Medicines Stock (NASDAQ:PRAX)

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

PRAX Stock Price History

PRAX Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
PRAX Apr 2024 60.000 call
PRAX May 2024 22.500 call
See More Headlines
Receive PRAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/05/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRAX
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$103.00
High Stock Price Target
$150.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+119.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-123,280,000.00
Net Margins
-5,037.88%
Pretax Margin
-5,037.88%

Debt

Sales & Book Value

Annual Sales
$2.45 million
Book Value
$7.92 per share

Miscellaneous

Free Float
12,881,000
Market Cap
$620.82 million
Optionable
Optionable
Beta
2.89
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Marcio Silva De'Souza M.B.A. (Age 44)
    President, CEO & Director
    Comp: $1.18M
  • Mr. Timothy Edwin Kelly (Age 50)
    CFO & Treasurer
    Comp: $691.58k
  • Mr. Alex Nemiroff J.D. (Age 44)
    General Counsel & Secretary
    Comp: $577.34k
  • Dr. Steven Petrou B.Sc. (Hons.)
    Ph.D., Co-Founder & Chief Scientific Officer
  • Lauren Mastrocola
    VP of Finance & Principal Accounting Officer
  • Dr. Karl Hansen Ph.D.
    Chief Technical Operations Officer
  • Alex Kane
    VP of Investor Relations & Corporate Communications
  • Ms. Kelly McCue
    Chief People Officer
  • Ms. Alyssa J. S. Wyant (Age 49)
    Chief Regulatory & Quality Officer
  • Ms. Megan T. Sniecinski (Age 42)
    Chief Business Officer

PRAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Praxis Precision Medicines stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRAX shares.
View PRAX analyst ratings
or view top-rated stocks.

What is Praxis Precision Medicines' stock price target for 2024?

4 brokerages have issued 1 year price objectives for Praxis Precision Medicines' stock. Their PRAX share price targets range from $29.00 to $150.00. On average, they predict the company's share price to reach $103.00 in the next year. This suggests a possible upside of 119.7% from the stock's current price.
View analysts price targets for PRAX
or view top-rated stocks among Wall Street analysts.

How have PRAX shares performed in 2024?

Praxis Precision Medicines' stock was trading at $22.28 at the start of the year. Since then, PRAX stock has increased by 110.5% and is now trading at $46.89.
View the best growth stocks for 2024 here
.

When is Praxis Precision Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PRAX earnings forecast
.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) issued its earnings results on Tuesday, March, 5th. The company reported ($2.97) earnings per share for the quarter, topping analysts' consensus estimates of ($3.05) by $0.08. The company had revenue of $0.52 million for the quarter, compared to analysts' expectations of $0.30 million. Praxis Precision Medicines had a negative net margin of 5,037.88% and a negative trailing twelve-month return on equity of 151.02%.

What ETF holds Praxis Precision Medicines' stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 25,514 shares of PRAX stock, representing 0.92% of its portfolio.

When did Praxis Precision Medicines' stock split?

Praxis Precision Medicines shares reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Praxis Precision Medicines IPO?

Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

Who are Praxis Precision Medicines' major shareholders?

Praxis Precision Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include PCG Wealth Advisors LLC (0.10%). Insiders that own company stock include Alex Nemiroff, Dean J Mitchell, Jill Desimone, Lauren Mastrocola, Marcio Souza, Parallel Master Fund LP Bsof and Timothy Edwin Kelly.
View institutional ownership trends
.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRAX) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners